Dextrothyroxine

From Wikipedia, the free encyclopedia

Dextrothyroxine

Systematic (IUPAC) name
(2R)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid
Clinical data
Trade names	Choloxin
AHFS/Drugs.com	Multum Consumer Information
Pregnancy cat.	B (US)
Legal status	Discontinued
Identifiers
CAS number	51-49-0
ATC code	C10AX01
PubChem	CID 8730
DrugBank	DB00509
ChemSpider	8402
UNII	4W9K63FION
ChEBI	CHEBI:30659
ChEMBL	CHEMBL559
Synonyms	D-3,5,3',5'-tetraiodothyronine
Chemical data
Formula	C₁₅H₁₁I₄N O₄
Mol. mass	776.87 g/mol
SMILES O=C(O)[C@H](N)Cc2cc(I)c(Oc1cc(I)c(O)c(I)c1)c(I)c2
InChI InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m1/s1 Key:XUIIKFGFIJCVMT-GFCCVEGCSA-N

Dextrothyroxine (trade name Choloxin) saw research as an cholesterol-lowering drug^[1]^[2] but was pulled due to cardiac side-effects. It also increases hepatic lipase which in turn improves utilization of triglycerides, improving apolipoprotein E cholesterol particles.^{[citation needed]}

References

↑ Bantle, J. P.; Hunninghake, D. B.; Frantz, I. D.; Kuba, K.; Mariash, C. N.; Oppenheimer, J. H. (1984). "Comparison of effectiveness of thyrotropin-suppressive doses of D- and L-thyroxine in treatment of hypercholesterolemia". The American journal of medicine 77 (3): 475–481. PMID 6475988.
↑ Bommer, C.; Werle, E.; Walter-Sack, I.; Keller, C.; Gehlen, F.; Wanner, C.; Nauck, M.; März, W.; Wieland, H.; Bommer, J. (1998). "D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients". Journal of the American Society of Nephrology : JASN 9 (1): 90–96. PMID 9440092.

Lipid modifying agents (C10)

GI tract

Cholesterol absorption inhibitors, NPC1L1	Ezetimibe SCH-48461

Bile acid sequestrants/resins (LDL)	Cholestyramine Colestipol Colestilan Colextran Colesevelam

Liver

Statins (HMG-CoA reductase, LDL)	Simvastatin^# Atorvastatin Fluvastatin Lovastatin Mevastatin Pitavastatin Pravastatin Rosuvastatin Cerivastatin^‡

Niacin and derivatives (HDL and LDL)	Niceritrol Niacin Nicofuranose Aluminium nicotinate Nicotinyl alcohol Acipimox

MTTP inhibitors (VLDL)	Dirlotapide Lomitapide Mitratapide

Blood vessels

Fibrates (PPAR)	Clofibrate^‡ Bezafibrate Aluminium clofibrate Gemfibrozil Fenofibrate Simfibrate Ronifibrate Ciprofibrate Etofibrate Clofibride Clinofibrate

CETP inhibitors (HDL)	Anacetrapib^† Dalcetrapib^§ Evacetrapib^§ Torcetrapib^†

Combinations

Other

Dextrothyroxine^‡
Probucol
Tiadenol
Benfluorex
Meglutol
Omega-3-triglycerides
Magnesium pyridoxal 5-phosphate glutamate
Policosanol
Lapaquistat^§
Mipomersen
Alipogene tiparvovec

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

M: MET

mt, k, c/g/r/p/y/i, f/h/s/l/o/e, a/u, n, m

k, cgrp/y/i, f/h/s/l/o/e, au, n, m, epon

m (A16/C10), i (k, c/g/r/p/y/i, f/h/s/o/e, a/u, n, m)

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.

Dextrothyroxine

See also

References